DE2649925C2 - 5,5-Dimethyl-3-[4-nitro-3-(trifluormethyl)-phenyl]-2-imidazolidinone, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel - Google Patents

5,5-Dimethyl-3-[4-nitro-3-(trifluormethyl)-phenyl]-2-imidazolidinone, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel

Info

Publication number
DE2649925C2
DE2649925C2 DE2649925A DE2649925A DE2649925C2 DE 2649925 C2 DE2649925 C2 DE 2649925C2 DE 2649925 A DE2649925 A DE 2649925A DE 2649925 A DE2649925 A DE 2649925A DE 2649925 C2 DE2649925 C2 DE 2649925C2
Authority
DE
Germany
Prior art keywords
nitro
phenyl
trifluoromethyl
dimethyl
imidazolidinones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2649925A
Other languages
German (de)
English (en)
Other versions
DE2649925A1 (de
Inventor
Claude Bry-Sur-Marne Bonne
Pierre Paris Girault
Jacques Perronnet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Publication of DE2649925A1 publication Critical patent/DE2649925A1/de
Application granted granted Critical
Publication of DE2649925C2 publication Critical patent/DE2649925C2/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Electromechanical Clocks (AREA)
DE2649925A 1975-10-29 1976-10-29 5,5-Dimethyl-3-[4-nitro-3-(trifluormethyl)-phenyl]-2-imidazolidinone, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel Expired DE2649925C2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7533084A FR2329276A1 (fr) 1975-10-29 1975-10-29 Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant

Publications (2)

Publication Number Publication Date
DE2649925A1 DE2649925A1 (de) 1977-05-12
DE2649925C2 true DE2649925C2 (de) 1986-08-28

Family

ID=9161795

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2649925A Expired DE2649925C2 (de) 1975-10-29 1976-10-29 5,5-Dimethyl-3-[4-nitro-3-(trifluormethyl)-phenyl]-2-imidazolidinone, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel

Country Status (18)

Country Link
US (1) US4097578A (cg-RX-API-DMAC7.html)
JP (1) JPS6011701B2 (cg-RX-API-DMAC7.html)
AU (1) AU500542B2 (cg-RX-API-DMAC7.html)
BE (1) BE847742A (cg-RX-API-DMAC7.html)
BG (1) BG60533B2 (cg-RX-API-DMAC7.html)
CA (1) CA1086751A (cg-RX-API-DMAC7.html)
CH (1) CH599164A5 (cg-RX-API-DMAC7.html)
DE (1) DE2649925C2 (cg-RX-API-DMAC7.html)
DK (1) DK152125C (cg-RX-API-DMAC7.html)
ES (1) ES452746A1 (cg-RX-API-DMAC7.html)
FR (1) FR2329276A1 (cg-RX-API-DMAC7.html)
GB (1) GB1518444A (cg-RX-API-DMAC7.html)
GE (1) GEP19970948B (cg-RX-API-DMAC7.html)
IE (1) IE43875B1 (cg-RX-API-DMAC7.html)
LU (2) LU76085A1 (cg-RX-API-DMAC7.html)
NL (2) NL187102C (cg-RX-API-DMAC7.html)
SE (1) SE430502B (cg-RX-API-DMAC7.html)
SU (1) SU596165A3 (cg-RX-API-DMAC7.html)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1138334A (en) * 1977-10-28 1982-12-28 Karl Bernauer Pharmaceutical preparations containing certain urea derivatives
MC1220A1 (fr) * 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
FI801184A7 (fi) * 1979-04-24 1981-01-01 F Hoffmann La Roche & Co Menetelmä imidatsolidiini-johdannaisten valmistamiseksi.
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
ATE75947T1 (de) * 1984-08-02 1992-05-15 Labrie Fernand Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs.
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US5084472A (en) * 1986-11-04 1992-01-28 Roussel Application of 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4'-dimethylimidazoline 2,5-dione in the treatment of hormone-dependent cancers other than that of the prostate
IT1214735B (it) * 1986-11-04 1990-01-18 Roussel Maestretti Spa Impiego di 1-(3'-trifluorometil 4'nitrofenil) 4,4-dimetilimidazolin2,5-dione per il trattamento di cancri ormonodipendenti diverso da quello della prostata
FR2619381B1 (fr) * 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
FR2656302B1 (fr) * 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
FR2671348B1 (fr) * 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
USRE35956E (en) * 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US6002016A (en) * 1991-12-20 1999-12-14 Rhone-Poulenc Agrochimie Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones
FR2706456B1 (fr) * 1993-06-18 1996-06-28 Rhone Poulenc Agrochimie Dérivés optiquement actifs de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
FR2685328B1 (fr) * 1991-12-20 1995-12-01 Rhone Poulenc Agrochimie Derives de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US6008370A (en) * 1992-11-25 1999-12-28 Rhone-Poulenc Agrochimie Fungicidal-2-alkoxy/haloalkoxy-1-(mono- or disubstituted)amino-4,4-disubstituted-2-imidazolin-5-ones
FR2724169B1 (fr) * 1994-09-06 1997-01-03 Roussel Uclaf Nouvelles phenylimidazolidines eventuellement substituees, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
FR2715402B1 (fr) * 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) * 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2725206B1 (fr) * 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
AU2001288213B2 (en) * 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
EP1854798A3 (en) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2002322493A1 (en) * 2001-07-10 2003-01-29 Ams Research Corporation Surgical kit for treating prostate tissue
AU2002364082A1 (en) 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7354933B2 (en) * 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
BRPI0413820A (pt) * 2003-08-22 2006-10-24 Ligand Pharm Inc derivados de 6-cicloamino-2-quinolinona como compostos moduladores de receptor de androgênio
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
AU2004305075A1 (en) * 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
NZ550102A (en) * 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
CN101056862B (zh) * 2004-09-10 2013-03-13 詹森药业有限公司 作为选择性雄激素受体调节剂（sarms）的咪唑烷-2-酮衍生物
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR101332924B1 (ko) 2005-05-13 2013-11-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
EP1891067B1 (en) * 2005-06-17 2016-01-13 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
SI3412290T1 (sl) 2006-03-27 2021-09-30 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
CN102755318B (zh) 2006-03-29 2014-09-10 加利福尼亚大学董事会 二芳基硫代乙内酰脲化合物
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
US9232959B2 (en) 2007-01-02 2016-01-12 Aquabeam, Llc Multi fluid tissue resection methods and devices
US12290277B2 (en) 2007-01-02 2025-05-06 Aquabeam, Llc Tissue resection with pressure sensing
JP5369336B2 (ja) 2007-01-02 2013-12-18 アクアビーム エルエルシー 前立腺の疾患を治療するための侵襲性が最小である方法及びデバイス
US20080245375A1 (en) * 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
PE20121470A1 (es) 2007-10-26 2012-11-18 Univ California Compuestos de diarilhidantoina como antagonistas del receptor de androgeno
EP3622910B1 (en) 2008-03-06 2024-07-10 AquaBeam LLC Tissue ablation and cautery with optical energy carried in fluid stream
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
US9848904B2 (en) 2009-03-06 2017-12-26 Procept Biorobotics Corporation Tissue resection and treatment with shedding pulses
WO2014127242A2 (en) 2013-02-14 2014-08-21 Procept Biorobotics Corporation Aquablation aquabeam eye surgery methods and apparatus
FR2944524B1 (fr) * 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
WO2016004071A1 (en) 2014-06-30 2016-01-07 Procept Biorobotics Corporation Fluid jet tissue resection and cold coagulation (aquablation) methods and apparatus
US9108944B2 (en) 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
EP2672958A1 (en) 2011-02-08 2013-12-18 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
JP6080872B2 (ja) 2012-02-29 2017-02-15 プロセプト バイオロボティクス コーポレイション 自動化された画像誘導組織切除および治療
LT3305285T (lt) 2012-09-26 2020-12-10 Aragon Pharmaceuticals, Inc. Anti-androgenai, skirti gydyti nametastazavusį kastracijai atsparų prostatos vėžį
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP2959013A2 (en) 2013-02-25 2015-12-30 Novartis AG Novel androgen receptor mutation
EP3041422A4 (en) 2013-09-06 2017-04-12 Procept Biorobotics Corporation Automated image-guided tissue resection and treatment
CN107072591B (zh) 2014-09-05 2021-10-26 普罗赛普特生物机器人公司 与靶器官图像的治疗映射结合的医师控制的组织切除
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3500310A1 (en) 2016-08-20 2019-06-26 FTF Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
CN107216290B (zh) * 2017-06-12 2021-03-16 陕西科技大学 一种3-丁基-5,5-二甲基海因咪唑季铵盐及其制备方法
CA3079135A1 (en) 2017-10-16 2019-04-25 Arturo Molina Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
MX2021012690A (es) 2019-04-19 2022-01-31 Ligand Pharm Inc Formas cristalinas y metodos para producir formas cristalinas de un compuesto.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB997037A (en) * 1962-03-19 1965-06-30 Ici Ltd New hydrantoin derivatives
JPS4920973B1 (cg-RX-API-DMAC7.html) * 1970-05-28 1974-05-29
JPS5136332B1 (cg-RX-API-DMAC7.html) * 1970-12-09 1976-10-07
IL45459A (en) * 1973-09-03 1978-01-31 Ciba Geigy Ag 1-(dichlorofluoromethylthio)-3-phenyl-imidazolidine-2,4-dione derivatives their preparation and their use as bactericides and fungicides

Also Published As

Publication number Publication date
LU76085A1 (cg-RX-API-DMAC7.html) 1977-05-31
DK152125B (da) 1988-02-01
CA1086751A (fr) 1980-09-30
AU1909576A (en) 1978-05-04
US4097578A (en) 1978-06-27
FR2329276A1 (fr) 1977-05-27
SE7610859L (sv) 1977-04-30
JPS5257176A (en) 1977-05-11
JPS6011701B2 (ja) 1985-03-27
BE847742A (fr) 1977-04-28
DE2649925A1 (de) 1977-05-12
DK487476A (da) 1977-04-30
NL930079I2 (nl) 1993-10-01
FR2329276B1 (cg-RX-API-DMAC7.html) 1979-09-14
GB1518444A (en) 1978-07-19
BG60533B2 (bg) 1995-07-28
IE43875L (en) 1977-04-29
GEP19970948B (en) 1997-04-18
NL187102B (nl) 1991-01-02
NL930079I1 (nl) 1993-09-16
ES452746A1 (es) 1977-10-01
AU500542B2 (en) 1979-05-24
CH599164A5 (cg-RX-API-DMAC7.html) 1978-05-12
SE430502B (sv) 1983-11-21
SU596165A3 (ru) 1978-02-28
NL187102C (nl) 1991-06-03
DK152125C (da) 1988-06-20
NL7611576A (nl) 1977-05-03
IE43875B1 (en) 1981-06-17
LU88282I2 (fr) 1994-05-04

Similar Documents

Publication Publication Date Title
DE2649925C2 (de) 5,5-Dimethyl-3-[4-nitro-3-(trifluormethyl)-phenyl]-2-imidazolidinone, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
DE2904552C2 (de) 2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridin-3,5-dicarbonsäure-3-(1-benzylpyrrolidin-3-yl)ester-5-niedrigalkylester
DE2203373A1 (de) Neue Imidazolinderivate,Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Praeparate
DE3878790T2 (de) Organo-anorganische vanadyl-verbindung, verfahren zur herstellung einer solchen verbindung, pharmazeutische zusammensetzung, die diese organo-anorganische verbindung enthaelt.
DE3009071A1 (de) 2-isopropylaminopyrimidinhydroxyderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE1470074C3 (de) 1,2,3,4,6,7-Hexahydro-l lbH-benzo eckige Klammer auf a eckige Klammer zu chinolizine sowie deren Acetate und/oder phsiologisch verträgliche Säureadditionssalze sowie Verfahren zu ihrer Herstellung
DE3336292A1 (de) Neue dichlorderivate der 16(alpha)-methylpregnanreihe, deren herstellung, deren verwendung als arzneimittel und die sie enthaltenden zusammensetzungen
DE2912835A1 (de) Steroidspirooxazolidinonderivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
DE1670059C3 (de) 1-Methyl- l-(2'-pyridylmethyl)guanidine
DE2428039C3 (de) Arzneimittel mit choleretischer Wirkung, enthaltend 2,6-Dihydroxycineol
CH645019A5 (de) Loesungsmittelgemisch und verfahren zur herstellung von parenteral verabreichbaren injektionsloesungen.
EP0031591A1 (de) 2,2-Dimethyl-3-oxoandrosta-4,6-dien-17S-spiro-5'-(2'-oxo-3'-methyloxazolidin), Verfahren zu seiner Herstellung und dieses enthaltende Arzneimittel
DE2508775C2 (de) 3-oxo-17β-n-amyloxyöstra-4,9,11-trien, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zusammensetzung
DE3102026C2 (cg-RX-API-DMAC7.html)
DE2708666C3 (de) Arzneimittel mit immunoregulativer und antiphlogistischer Wirkung
DE2739659C3 (de) N-2,6-Dichlorphenyl-2-aminopyrimidin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
DE2113489B2 (de) 2-Nitro-benzofuranderivate, ein Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel
DE2362718A1 (de) 2,2-dimethylsteroide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
DE2527579A1 (de) Neue pharmazeutische zusammensetzungen
DE2656574A1 (de) Neue 1,6-naphthyridincarbonsaeurederivate und verfahren zu ihrer herstellung
DE1815466C (de) 3 (5 Nitro 2 furfurylidenamino)-oxazoli done (2)
DE973048C (de) Verfahren zur Herstellung von als Heilmittel geeigneten substituierten Morpholinen
DE1593515C3 (de) 6-Chlor-21 -fluor-1,2alpha-methylen-DeKa hoch 4,6 -pregnadiene, Verfahren zu deren Herstellung sowie diese enthaltende Mittel
DE2752339C3 (de) Arzneimittel mit Depotwirkung zur Behandlung des Mammakarzinoms
DE1468681C3 (de) 17beta-Tetrahydropyranyloxy verbindungen der Androstanreihe sowie Verfahren zu ihrer Herstellung und Heilmittel

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8128 New person/name/address of the agent

Representative=s name: ASSMANN, E., DIPL.-CHEM. DR.RER.NAT. KLINGSEISEN,

D2 Grant after examination
8364 No opposition during term of opposition